News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Cynata Therapeutics.
RELATED STOCKHEAD STORIES
News
Closing Bell: ASX phones in more gains as prices plunge in Beijing and records tumble in New York
Health & Biotech
ASX Health Stocks: More positive data for Recce’s drug, Cynata expects trial results in Q1
Health & Biotech
ASX Health Stocks: Althea says its cannabis beverage could generate $5m of sales in Canada
Health & Biotech
ASX Health Stocks: Medibio jumps 50pc on Phase 1 results; Cann doubles cannabis harvest
Experts
Dr Boreham’s Crucible: Is this a case of what’s good for Mesoblast is good for Cynata?
News
CLOSING BELL: Welcome to the ASX, where our motto is ‘chin up, mate… it could’ve been worse’
Health & Biotech
ASX Health Stocks: Pharmaxis and Aroa lift on FDA news, Cynata to commence Phase 2 trial
News
Closing Bell: RBA Board finally bottles out, snapping its 10-month winning streak
Health & Biotech
The chances of Phase 3 success, and the ASX health stocks that are close to a home run
Health & Biotech
Which ASX stocks are on the path from FDA to clinical trial in 2023?
Health & Biotech
ASX Health Stocks: Patent updates from Cynata and Proteomics; Ramsay sees good times ahead
Health & Biotech
ASX Biotech Stocks: HitIQ nabs landmark deal with Premier League for its concussion management tech
Health & Biotech
ASX Health Stocks: Patrys crosses brain barrier, opens up possibilities for its deoxymab antibody
Health & Biotech
ASX Health Stocks: Cynata races ahead after getting green light for diabetic foot ulcer clinical trial
Health & Biotech
ASX Health Stocks: Botanix seeks nod from US FDA; PainChek goes big in Japan
Health & Biotech
ASX Health Stocks: Avita tumbles 16pc as RECELL study results disappoint investors
Health & Biotech
